Minouk J Schoemaker
Overview
Explore the profile of Minouk J Schoemaker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
142
Citations
6791
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Justeau G, Chouaid C, Debieuvre D, Audigier-Valette C, Quantin X, Lena H, et al.
Front Oncol
. 2025 Mar;
15:1526931.
PMID: 40052124
Introduction: This study describes treatment and retreatment patterns and outcomes in patients in France following nivolumab as a second-line or later (2L+) treatment in locally advanced or metastatic non-small cell...
2.
Johnsen S, Baas P, Sorensen J, Chouaid C, Griesinger F, Daumont M, et al.
Future Oncol
. 2025 Feb;
21(7):867-878.
PMID: 39996596
In recent years, the thoracic malignancies treatment landscape has become more complex with the emergence of novel targeted and immunotherapy-based treatments. Although beneficial to patients and physicians, this fast-paced therapeutic...
3.
Kresovich J, Guranich C, Houghton S, Qian J, Jones M, Boutot M, et al.
Breast Cancer Res
. 2024 Nov;
26(1):169.
PMID: 39593118
Background: Prolactin, a hormone produced by the pituitary gland, regulates breast development and may contribute to breast cancer etiology. However, most epidemiologic studies of prolactin and breast cancer have been...
4.
Sorensen J, Baas P, Szepligeti S, Pedersen A, Johnsen S, Carroll R, et al.
Acta Oncol
. 2024 Aug;
63:649-657.
PMID: 39114950
Background: Malignant pleural mesothelioma (MPM) is a rare thoracic malignancy with poor prognosis and limited treatment options. Immunotherapy shows potential for improved outcomes; however, real-world evidence on its use will...
5.
Saner F, Takahashi K, Budden T, Pandey A, Ariyaratne D, Zwimpfer T, et al.
Clin Cancer Res
. 2024 Jun;
30(16):3481-3498.
PMID: 38837893
Purpose: The purpose of this study was to evaluate RB1 expression and survival across ovarian carcinoma histotypes and how co-occurrence of BRCA1 or BRCA2 (BRCA) alterations and RB1 loss influences...
6.
Oskarsdottir G, Lampa E, Berglund A, Rosengren L, Ulvestad M, Boros M, et al.
Cancers (Basel)
. 2024 May;
16(9).
PMID: 38730607
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide, with ~40-50% of patients diagnosed with non-metastatic disease (stages IA-IIIC). The treatment landscape is evolving rapidly as immunotherapies...
7.
Holle A, Adami H, Baglietto L, Berrington de Gonzalez A, Bertrand K, Blot W, et al.
Cancer Epidemiol
. 2024 Feb;
89:102545.
PMID: 38377945
Background: A high body mass index (BMI, kg/m) is associated with decreased risk of breast cancer before menopause, but increased risk after menopause. Exactly when this reversal occurs in relation...
8.
Timmins I, Jones M, OBrien K, Adami H, Aune D, Baglietto L, et al.
J Clin Oncol
. 2023 Dec;
42(8):927-939.
PMID: 38079601
Purpose: There is strong evidence that leisure-time physical activity is protective against postmenopausal breast cancer risk but the association with premenopausal breast cancer is less clear. The purpose of this...
9.
Saner F, Takahashi K, Budden T, Pandey A, Ariyaratne D, Zwimpfer T, et al.
medRxiv
. 2023 Nov;
PMID: 37986741
Background: Somatic loss of the tumour suppressor RB1 is a common event in tubo-ovarian high-grade serous carcinoma (HGSC), which frequently co-occurs with alterations in homologous recombination DNA repair genes including...
10.
Swerdlow A, Jones M, Slater S, Burden A, Botha J, Waugh N, et al.
Int J Cancer
. 2023 May;
153(3):512-523.
PMID: 37190903
Type 2 diabetes is associated with raised risk of several cancers, but for type 1 diabetes risk data are fewer and inconsistent We assembled a cohort of 23 473 UK...